Is that Why vTv Therapeutics (Nasdaq: VTVT) Inc shares drowned in the late hours last night?
vTv Therapeutics (Nasdaq: VTVT) shares thwarted in the after-market hours to -37.71% to $1.85 after the company revealed that it had signed a worldwide license agreement with Anteris Bio for the world’s first clinical-stage Nrf2 activator compound, HPP971. The biotech investment firm Aditum Bio, co-founded in 2019 by former Novartis executives Joe Jimenez and Dr. […]